Showing 3641-3650 of 5773 results for "".
- Genentech Voluntarily Recalls Susvimo Ocular Implant for Wet AMDhttps://modernod.com/news/genentech-voluntarily-recalls-susvimo-ocular-implant-for-wet-amd/2481185/Roche and Genentech announced a voluntarily recall of the Susvimo (ranibizumab injection) ocular implant for wet AMD, citing a manufacturing problem with the device. In addition, the companies announced that new implantations, including in ongoing global clinical trials, have been paused.
- Lori Tierney Joins Johnson & Johnson Vision as President of Americashttps://modernod.com/news/lori-tierney-joins-johnson-johnson-vision-as-president-of-americas/2481184/Johnson & Johnson Vision announced that Lori Tierney has joined the company as President of Americas. In this critical leadership role, Ms. Tierney will have full accountability for shaping the strategy and driving industry-leading growth of the vision care portfolio in both North America and
- Eyenuk Secures $26 Million Series A Funding to Accelerate Global Access to AI-Powered Eye-Screening Technologyhttps://modernod.com/news/eyenuk-secures-26-million-series-a-funding-to-accelerate-global-access-to-ai-powered-eye-screening-technology/2481183/Eyenuk announced it has secured $26 million in a Series A financing round, bringing the company’s total funding to over $43 million. The capital raise was led by AXA IM Alts and was joined by new and existing investors including T&W Medical A/S, A&C Foelsgaard Alternativer ApS,
- Azura Ophthalmics Expands Broad Intellectual Property Portfolio to 12 US and European Patentshttps://modernod.com/news/azura-ophthalmics-expands-broad-intellectual-property-portfolio-to-12-us-and-european-patents/2481182/Azura Ophthalmics announced the company’s US 11,459,351 patent (the ‘351 patent) was granted by the US Patent and Trademark Office. This patent strengthens the company’s extensive portfolio protecting its use of dual-action keratolytic drug conjugates in developme
- OcuTerra Reports Publication of OTT166 Safety and Biological Activity Data From Phase 1b Study in Diabetic Eye Diseasehttps://modernod.com/news/ocuterra-reports-publication-of-ott166-safety-and-biological-activity-data-from-phase-1b-study-in-diabetic-eye-disease/2481180/OcuTerra Therapeutics announced the publication of a paper titled “The Safety and Biological Activity of OTT166, a Novel Topical Selective Integrin Inhibitor for the Treatment of Diabetic Eye Disease: A Phase 1b Study” in Ophthalmic Surgery, Lasers and Imaging Retina (
- Lenstec Rebrands its Newly Approved Multifocal IOL to ClearView 3https://modernod.com/news/lenstec-rebrands-its-newly-approved-multifocal-iol-to-clearview-3/2481174/Lenstec announced that it has rebranded its new multifocal IOL, the SBL-3, to the ClearView 3 to better describe the vision patients can expect with the new IOL, according to Lenstec. The IOL was approved by the FDA in July 2022. "Since approval, the ClearView
- EyeCare Partners Expands Footprint in Northern Ohio with Three Additional Practiceshttps://modernod.com/news/eyecare-partners-expands-footprint-in-northern-ohio-with-three-additional-practices/2481171/EyeCare Partners announced that it has expanded its presence in Northern Ohio through a partnership with Novus Clinic, Corrective Eye Center, and Retina Specialists of Ohio (RSO). Additionally, the company plans to build a new Ambulatory Surgery Center (ASC) as well as a 16-exam lane clinic,
- Cellusion and Minaris Regenerative Medicine Enter Alliance for the Manufacturing of Corneal Endothelial Cell Regenerative Therapyhttps://modernod.com/news/cellusion-and-minaris-regenerative-medicine-enter-alliance-for-the-manufacturing-of-corneal-endothelial-cell-regenerative-therapy/2481170/Cellusion, a Japanese regenerative medicine startup aiming to solve the global corneal transplant waiting list problem, and Minaris Regenerative Medicine, a global contract and development manufacturing organization, announced a Letter of Intent (LOI) of the Manufacturing of CLS001 for a cor
- PatientPoint Acquires Rendia to Accelerate Expansion into Ophthalmology Specialtyhttps://modernod.com/news/patientpoint-acquires-rendia-to-accelerate-expansion-into-ophthalmology-specialty/2481166/PatientPoint announced the acquisition of Rendia, a provider of point-of-care content for eye care providers sold on a subscription basis. Terms of the deal were not disclosed. With PatientPoint’s expansion into ophthalmology and optometry, PatientPoint’
- Harrow Sells Non-Ophthalmic Compounding Businesshttps://modernod.com/news/harrow-sells-non-ophthalmic-compounding-business/2481162/Harrow announced the sale of its non‑ophthalmic compounding business to Innovation Compounding Pharmacy, LLC, an affiliate of Revelation Pharma Corporation. Financial terms of the deal were not disclosed. Revelation purchased the assets of Harrow’s non‑ophthalmic c